Relaxo Footwear

Buy

Superlative margin performance. Upgrade to Buy

- Revenue declined 7% YoY to Rs 5.8bn in Q2FY21 came ahead of our estimate. Lockdown in select geographies resulted in drop in revenues. Nevertheless, recovery in Q2 was better than our expectation.
- GM/EBITDA expanded by 510/520bps mainly due to benign RM prices and improved operating efficiencies during the quarter. Going ahead, the margins would remain high versus peers considering larger contribution of distribution business compared to retail business.
- In the long run, we believe that the company would continue its strong performance by increasing penetration in South and West and is likely to further benefit from premiumization. Relaxo should continue to outpace Bata in terms of revenue growth and the revenue gap would narrow, going ahead.
- We have upward revised our FY21E EPS estimates to Rs 9.2 (+9.6%) and FY22E EPS estimates to Rs 11.9 (+0.7%). We have introduced FY23E EPS estimates at Rs 13.6. We value the stock at 55x FY23E EPS to arrive at a TP of Rs 747. Upgrade to Buy.

Structural drivers in place to tackle challenging times

Post normalization of demand, we believe that the company would continue to increase its distribution reach in southern and western markets. In the short run, in case of down trading, we believe that Relaxo has better offerings compared to other players. Further, moderation in RM costs would help it to expand margins. In house manufacturing, strong distribution reach, increase in penetration are key levers for future growth. We continue to believe that the company has attractive product offerings and has the ability to premiumize portfolio at the lower end of the pyramid.

Results exceed our estimates

Revenue declined 7.4% YoY to Rs 5.8bn in Q2FY21 - was ahead of our estimate. With easing of Covid led restrictions, the company witnessed pickup in demand in Q2 with 2% volume growth. Operations are almost at pre-Covid levels. A 510bps/ 130bps decline in RM/other expenses respectively was partially offset by 120bps increase in staff costs. Consequently, EBITDA margin improved 520bps to 22.0%. EBITDA grew 21.2% YoY to Rs 1,269mn- came ahead of our estimate. Surge in other income was due to lease rent waiver for rented premises. ETR for Q2FY21 was not comparable with Q2FY20 as the company had recognized full impact of new tax regime in Q2FY20. APAT increased 6.5% YoY to Rs 751mn

Q2FY21 Result (Rs Mn)

Particulars	Q2FY21	Q2FY20	YoY (%)	Q1FY21	QoQ (%)
Revenue	5,759	6,218	(7.4)	3,636	58.4
Total Expense	4,490	5,171	(13.2)	3,066	46.5
EBITDA	1,269	1,047	21.2	570	122.6
Depreciation	278	278	0.1	275	1.0
EBIT	991	770	28.8	295	235.8
Other Income	50	17	205.5	69	(26.7)
Interest	38	43	(11.6)	41	(6.6)
EBT	1,004	743	35.1	323	210.5
Тах	253	38	571.5	81	211.7
RPAT	751	705	6.5	242	210.1
APAT	751	705	6.5	242	210.1
			(bps)		(bps)
Gross Margin (%)	61.4	56.3	506	49.9	1143
EBITDA Margin (%)	22.0	16.8	519	15.7	635
NPM (%)	13.0	11.3	170	6.7	638
Tax Rate (%)	25.2	5.1	2010	25.1	10
EBIT Margin (%)	17.2	12.4	483	8.1	909



СМР	Rs 660				
Target / Upside	Rs 747 / 13				
NIFTY		1	1,669		
Scrip Details					
Equity / FV	Rs 248mn / Rs 2				
Market Cap	Rs 164br				
	USD 2br				
52-week High/Low	Rs 830/ 500				
Avg. Volume (no)	2,19,388				
Bloom Code	RLXF IN				
Price Performance	1M	3M	12M		
Absolute (%)	0	11	21		
Rel to NIFTY (%)	(2)	5	22		

Shareholding Pattern

	Mar'20	Jun'20	Sep'20
Promoters	71.0	71.0	71.0
MF/Banks/FIs	19.9	19.2	19.1
FIIs	3.0	3.3	3.4
Public / Others	6.2	6.6	6.6

Valuation (x)

	FY21E	FY22E	FY23E
P/E	71.5	55.4	48.6
EV/EBITDA	39.1	31.6	27.5
ROE (%)	16.8	18.6	18.1
RoACE (%)	17.4	19.2	18.6

Estimates (Rs mn)

	FY21E	FY22E	FY23E
Revenue	22,681	28,257	32,300
EBITDA	4,165	5,119	5,801
PAT	2,292	2,954	3,372
EPS (Rs.)	9.2	11.9	13.6

VP Research: Sachin Bobade

Tel: +91 22 40969731 E-mail: sachinb@dolatcapital.com

Associate: Nikhat Koor

Tel: +91 22 40969764 E-mail: nikhatk@dolatcapital.com



EBITDA margins to remain elevated

We expect down trading post re-opening of lockdown mainly due to economic uncertainties and job losses during the pandemic. In addition, work from home policies and restricted travel would lead to higher sales of informal footwear (open slippers, floaters) than formal. In light of expected down trading, Relaxo has better product offering at the bottom of the pyramid (~2/3rd revenue) compared to other players like Bata. In addition, operating leverage continues to remain a key positive for Relaxo. Less dependency on retail model vs distribution model would help the company to maintain margins, going ahead. However, we believe that the Q2FY21 margins are not sustainable as RM prices have started increasing. We expect margins to normalize hereon but would remain on the higher side compared to historical performance. We have estimated +18% margins for Relaxo vs 14-16% reported historically.

Improvement led by North and East region

The recovery was led by North and East regions as most of the states opened up faster compared to rest of India. However, West and South posted significant decline as Maharashtra and Kerala remained closed for a longer period. Despite close down of high growth markets, Relaxo posted 2% volume growth, implying strong performance.

Exhibit I. QZI IZI Actu	al V/S DAILI CSUI	lates	
Rs mn	Actual	Estimates	Variance (%) Comments
Revenue	5,759	5,347	7.7 Higher than estimates due to lesser than expected impact of lockdown
EBITDA	1,269	917	38.4
EBITDA margin %	22.0	17.2	490 Variation as RM costs were lower than estimates
APAT	751	517	45.4 Cascading effect of higher EBITDA

Exhibit 1: Q2FY21 Actual V/s DART estimates

Source: Company, DART

Exhibit 2: Change in estimates

Rs Mn	FY21E				FY22E	
	New	Previous	Chg (%)	New	Previous	Chg (%)
Revenue	22,681	22,681	-	28,257	28,257	-
EBITDA	4,165	3,897	6.9	5,119	5,092	0.5
EBITDA Margin (%)	18.4	17.2	120	18.1	18	10
PAT	2,292	2,091	9.6	2,954	2,934	0.7
EPS (Rs)	9.2	8.4	9.6	11.9	11.8	0.7

Source: Company, DART

Though Q2FY21 revenue was a beat, we have maintained our revenue forecast as current estimates factors in improvement in H2FY21. However, we have upward revised our margin estimates as Q2FY21 margins were significantly higher than our consideration. In line with the revision in EBITDA and margin, we have revised our EPS estimates.



Particulars (Rs.mn)	Q2FY21	Q2FY20	YoY (%)	Q1FY21	QoQ (%)	H1FY21	H1FY20	YoY (%)
Net Sales	5,759	6,218	(7.4)	3,636	58.4	9,395	12,701	(26.0)
Expenditure	4,490	5,171	(13.2)	3,066	46.5	7,555	10,589	(28.7)
Raw Materials	2,224	2,716	(18.1)	1,820	22.2	4,044	5 <i>,</i> 692	(28.9)
Staff Cost	736	722	1.9	567	29.7	1,303	1,446	(9.9)
Other Expenditure	1,530	1,733	(11.7)	679	125.4	2,209	3,452	(36.0)
Operating Profit	1,269	1,047	21.2	570	122.6	1,839	2,111	(12.9)
Other Income	50.4	16.5	205.5	68.8	(26.7)	119	29	312.5
Interest	38.1	43.1	(11.6)	40.8	(6.6)	78.9	89.7	(12.0)
Depreciation	278	278	0.1	275	1.0	553	543	1.8
PBT	1,004	743	35.1	323	210.5	1,327	1,508	(12.0)
Тах	253	38	571.5	81	211.7	334	305	9.5
APAT	751	705	6.5	242	210.1	993	1,203	(17.4)
RPAT	751	705	6.5	242	210.1	993	1,203	(17.4)
			bps		bps		·	bps
Gross Margin (%)	61.4	56.3	510	49.9	1,140	57.0	55.2	180
Staff Cost (%)	12.8	11.6	120	15.6	(280)	13.9	11.4	250
Other Expenditure (%)	26.6	27.9	(130)	18.7	790	23.5	27.2	-370
EBITDA(%)	22.0	16.8	520	15.7	640	19.6	16.6	300
Tax rate (%)	25.2	5.1	2,010	25.1	10	25.1	20.2	490
NPM (%)	13.0	11.3	170	6.7	640	10.6	9.5	110

Exhibit 3: Half Yearly Performance

Source: Company, DART

Conference Call Key Takeaways

- There was a delay in commencing production amidst high demand scenario which impacted Q2 revenue to some extent. In October'20, company witnessed good recovery in sales with festive demand.
- EBO's totaled 396 at the end of H1FY21, contributed ~5% of revenue. The company added 6 new stores during H1. Company plans to end FY21E with 400 stores. Pressure on EBO's remains due to low footfalls.
- Exports are picking up with opening up of markets and contribute 4% of revenue.
- The company witnessed good demand pickup in rural in Q2FY21. Number of dealers and distributors has increased in order to cater to rising demand of open footwear.
- While closed Sparx footwear hampered performance, Hawaii, Flite and Bahamas open footwear exhibited strong growth. Sparx contributed ~1/3rd of revenue in Q2. As per the management, demand for open footwear is likely to be resilient for next 2-3 years, with new work from home policies.
- E-com (~10% contribution) grew 10% YoY in Q2FY21. Company targets ~10-12% contribution from E-com for next 6-12 months.
- Volume growth in Q2FY21 was 2% (value de-growth 7%) while that of H1FY21 it was -13% (value de-growth 26%). The difference in value and volume growth was due to mix change as low value open footwear were high selling.
- Raw material costs are currently benign but are likely to inch upwards in Q4. Company may review prices if there is significant increase in RM costs.



- EBITDA margins are likely to improve in FY21E compared to previous year. However, it is not expected to sustain at Q2 levels of 22% due to anticipated increase in advertisement, brand building, travel costs, RM etc in H2FY21.
- Relaxo has 700 distributors and +50K MBO's across India. However, the footwear universe in India includes 100K MBO's, as per the management. Relaxo targets to grow MBO reach by double digits every year.
- The share of closed footwear in Relaxo's portfolio is 10% in volume terms and 20% in value terms.
- The company did not witness demand of school shoes yet.
- Company expects to incur capex of `1bn in FY21E, same range as previous years.
- Relaxo has increased the amount of deposit from distributors in last 6 months. Security amount is similar for new and existing distributor.





Exhibit 5: EBITDA and EBITDA margin




Source: Company, DART

Source: Company, DART

Exhibit 6: Gross margin (%) 59.8 62 00 56.8 60 5. m 55.0 56. 58 54. 56 52.8 53.0 53 33. <u>с</u> 54 49.9 52 50 48 Q4FY20 Q3FY19 Q1FY20 Q2FY20 Q3FY20 Q3FY18 Q4FY18 Q1FY19 Q1FY21 Q2FY21 Q2FY19 Q4FY19 Q2FY18

Source: Company, DART

Exhibit 7: Net Profit and Margin (%)



Source: Company, DART



(Rs Mn)	FY20A	FY21E	FY22E	FY23E
Revenue	24,105	22,681	28,257	32,300
Total Expense	20,015	18,516	23,138	26,499
COGS	10,393	9,479	12,044	13,814
Employees Cost	2,940	2,802	3,323	3,799
Other expenses	6,682	6,236	7,772	8,885
EBIDTA	4,090	4,165	5,119	5,801
Depreciation	1,094	1,149	1,200	1,325
EBIT	2,995	3,016	3,919	4,476
Interest	169	170	210	210
Other Income	91	210	230	230
Exc. / E.O. items	0	0	0	0
EBT	2,917	3,056	3,939	4,496
Tax	655	764	985	1,124
RPAT	2,263	2,292	2,954	3,372
Minority Interest	0	0	0	0
Profit/Loss share of associates	0	0	0	0
АРАТ	2,263	2,292	2,954	3,372

Balance S	Sheet
-----------	-------

(Rs Mn)	FY20A	FY21E	FY22E	FY23E
Sources of Funds				
Equity Capital	248	248	248	248
Minority Interest	0	0	0	0
Reserves & Surplus	12,475	14,358	16,902	19,865
Net Worth	12,723	14,606	17,150	20,113
Total Debt	191	191	191	191
Net Deferred Tax Liability	248	421	421	421
Total Capital Employed	13,162	15,218	17,762	20,725

Applications	of Funds
--------------	----------

	9,781	10,081	10,256
438	482	530	583
2	7	7	7
8,161	9,058	12,093	15,436
4,477	3,900	4,860	5,557
1,721	2,166	2,700	3,087
40	1,189	2,286	4,223
1,643	1,540	1,920	2,195
280	262	327	374
5,270	4,110	4,949	5,557
1,837	2,043	2,546	2,911
3,433	2,067	2,403	2,646
2,892	4,948	7,144	9,879
13,162	15,218	17,762	20,725
	2 8,161 4,477 1,721 40 1,643 280 5,270 1,837 3,433 2,892	2 7 8,161 9,058 4,477 3,900 1,721 2,166 40 1,189 1,643 1,540 280 262 5,270 4,110 1,837 2,043 3,433 2,067 2,892 4,948	2 7 7 8,161 9,058 12,093 4,477 3,900 4,860 1,721 2,166 2,700 40 1,189 2,286 1,643 1,540 1,920 280 262 327 5,270 4,110 4,949 1,837 2,043 2,546 3,433 2,067 2,403 2,892 4,948 2,892 4,948 7,144

E – Estimates



Particulars	FY20A	FY21E	FY22E	FY23E
(A) Margins (%)				
Gross Profit Margin	56.9	58.2	57.4	57.2
EBIDTA Margin	17.0	18.4	18.1	18.0
EBIT Margin	12.4	13.3	13.9	13.9
Tax rate	22.4	25.0	25.0	25.0
Net Profit Margin	9.4	10.1	10.5	10.4
(B) As Percentage of Net Sales (%)				
COGS	43.1	41.8	42.6	42.8
Employee	12.2	12.4	11.8	11.8
Other	27.7	27.5	27.5	27.5
(C) Measure of Financial Status				
Gross Debt / Equity	0.0	0.0	0.0	0.0
Interest Coverage	17.8	17.7	18.7	21.3
Inventory days	68	63	63	63
Debtors days	26	35	35	35
Average Cost of Debt	31.8	89.0	109.9	109.9
Payable days	28	33	33	33
Working Capital days	44	80	92	112
FA T/O	2.5	2.3	2.8	3.1
(D) Measures of Investment				
AEPS (Rs)	9.1	9.2	11.9	13.6
CEPS (Rs)	13.5	13.9	16.8	18.9
DPS (Rs)	2.6	1.7	1.7	1.7
Dividend Payout (%)	28.4	17.9	13.9	12.1
BVPS (Rs)	51.3	58.9	69.2	81.1
RoANW (%)	19.0	16.8	18.6	18.1
RoACE (%)	19.1	17.4	19.2	18.6
RoAIC (%)	23.6	22.2	26.6	28.0
(E) Valuation Ratios				
CMP (Rs)	660	660	660	660
P/E	72.4	71.5	55.4	48.6
Mcap (Rs Mn)	1,63,779	1,63,779	1,63,779	1,63,779
MCap/ Sales	6.8	7.2	5.8	5.1
EV	1,63,930	1,62,782	1,61,684	1,59,747
EV/Sales	6.8	7.2	5.7	4.9
EV/EBITDA	40.1	39.1	31.6	27.5
P/BV	12.9	11.2	9.5	8.1
Dividend Yield (%)	0.4	0.3	0.3	0.3
(F) Growth Rate (%)				
Revenue	5.2	(5.9)	24.6	14.3
EBITDA	26.1	1.8	22.9	13.3
EBIT	14.4	0.7	29.9	14.2
PBT	8.9	4.8	28.9	14.2
APAT	29.0	1.3	28.9	14.2
EPS	29.0	1.3	28.9	14.2
Cash Flow				
(Rs Mn)	FY20A	FY21E	FY22E	FY23E
CFO	3,190	2,707	3,055	3,900
CFI	(1,159)	(1,149)	(1,548)	(1,553)
	(2,014)	(410)	(410)	(410)
CFF	(_)= .,			
FCFF	2,032	1,563	1,507	2,347

E – Estimates



DART RATING MATRIX

Total Return Expectation	(12 Months)
---------------------------------	-------------

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

Rating and Target Price History



Month	Rating	TP (Rs.)	Price (Rs.)
Nov-19	Accumulate	635	564
Feb-20	Accumulate	806	721
Mar-20	Sell	536	594
Mar-20	Sell	536	575
Jun-20	Accumulate	773	720
Aug-20	Accumulate	651	640
Sep-20	Accumulate	651	649

*Price as on recommendation date

DART Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747		
Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745		
CONTACT DETAILS					
Equity Sales	Designation	E-mail	Direct Lines		
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709		
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735		
Yomika Agarwal	VP - Equity Sales	yomika@dolatcapital.com	+9122 4096 9772		
Jubbin Shah	VP - Derivatives Sales	jubbins@dolatcapital.com	+9122 4096 9779		
Ashwani Kandoi	AVP - Equity Sales	ashwanik@dolatcapital.com	+9122 4096 9725		
Lekha Nahar	AVP - Equity Sales	lekhan@dolatcapital.com	+9122 4096 9740		
Equity Trading	Designation	E-mail			
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728		
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707		
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702		
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715		
Dinesh Mehta	Co- Head Asia Derivatives	dinesh.mehta@dolatcapital.com	+9122 4096 9765		
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705		



Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. Entity/ persons only: This research report is a product of Dolat Capital Market Private Limited., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and a re not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Dolat Capital Market Private Limited. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person or entity.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Dolat Capital Market Private Limited. has entered into an agreement with a U.S. registered broker-dealer Ltd Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer/Entity as informed by Dolat Capital Market Private Limited. from time to time.



Dolat Capital Market Private Limited.

Corporate Identity Number: U65990DD1993PTC009797 Member: BSE Limited and National Stock Exchange of India Limited. SEBI Registration No: BSE - INB010710052 & INF010710052, NSE - INB230710031& INF230710031, Research: INH00000685 Registered office: Office No. 141, Centre Point, Somnath, Daman – 396 210, Daman & Diu Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com